Ozempic

News

Novo Nordisk's new chief executive Mike Doustdar

Novo Nordisk cuts guidance again on weaker GLP-1 growth

Novo Nordisk's first set of financial results under new CEO Mike Doustdar continues the theme of lower growth expectations for the company this year.

News

Novo Nordisk cuts GLP-1 prices for cash buyers

Novo Nordisk has said it will offer diabetes therapy Ozempic at $499 per month for cash-paying customers in the US.

News

Novo Nordisk weakens again on interim results readout

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the first half of this year.

News

Lilly trumpets heart health data with Mounjaro

Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 drugs for diabetes, with new data for Mounjaro on cardiovascular outcomes.

News

Novo Nordisk slumps as it cuts sales forecast, names new CEO

Novo Nordisk has a new CEO, facing an uphill battle to restore the fortunes of its US business as diabetes and obesity drugs come under pressure.

News

MHRA's chief safety officer, Dr Alison Cave

UK probes link between GLP-1 drugs and pancreatitis

The UK is studying cases of pancreatitis in people taking GLP-1 drugs for weight loss or type 2 diabetes to see if genetics may make them vulnerable.

Novo Nordisk cuts guidance again on weaker GLP-1 growth

Novo Nordisk cuts GLP-1 prices for cash buyers

Novo Nordisk weakens again on interim results readout

Lilly trumpets heart health data with Mounjaro

Novo Nordisk slumps as it cuts sales forecast, names new CEO

UK probes link between GLP-1 drugs and pancreatitis

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Ozempic

Editor's Picks